SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as investors debate whether the current price action signals a sustainable breakout or another temporary pump, with community sentiment sharply divided between long-term believers and vocal skeptics. Discussions are centered on the token's relationship with broader market movements and speculative hopes for future regulatory clarity and institutional adoption.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate is seeing a massive surge in trading volume and investor interest as the community positions itself ahead of a critical May FDA decision for its ADHD drug, CTx-1301. Investors are actively discussing the potential impact of an anticipated U.S. patent approval on the stock, drawing parallels to previous market rallies while debating the impact of recent financing moves on the company's long-term valuation.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is seeing heightened community engagement as traders react to the stock's high-beta correlation with Bitcoin and its ongoing transition into a crypto-focused treasury company. Discussion is currently polarized, with bulls pointing to the company's Bitcoin holdings and potential for long-term re-rating against net asset value, while bears frequently cite concerns over dilution, reverse splits, and the high costs of operational debt.

GODS token is the currency used in the blockchain-based online trading card game, Gods Unchained. The token will act as a governance so players will be able to decide the development direction of the game. Players can also use the token to mint rare cards. Most importantly, the GODS token will be an integral part of the play to earn concept of the game.

Gods Unchained

Gods Unchained is trending as the community speculates on a potential price breakout, citing its gaming utility and low market capitalization relative to peers as catalysts. Traders are actively debating technical patterns like the cup-and-handle and monitoring for a broader rotation into the gaming sector, with many expressing optimism for long-term growth and high-percentage gains.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The VanEck Gold Miners ETF (GDX) remains a major focal point as investors debate whether mining stocks can decouple from volatile gold and silver spot prices amidst ongoing geopolitical tensions and fiscal policy shifts. The community is actively discussing Elliott Wave technical patterns, potential margin calls, and the broader macro implications of central bank activity on the metals complex.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CytomX Therapeutics is seeing significant volatility and high trading volume following the release of promising Phase 1 expansion data for its colorectal cancer treatment, Varsetatug Masetecan. While bulls are energized by positive clinical signals and analyst price target upgrades, the community is actively debating the impact of the newly announced public offering and the long-term dilution risks inherent in clinical-stage drug development.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as investors debate whether potential integration into Xs upcoming payment system serves as a long-term catalyst or just a temporary pump. While some community members remain skeptical, citing historical price patterns and bearish sentiment, others are actively loading up on shares in anticipation of a significant breakout.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is trending amid a surge in institutional activity, highlighted by a notable streak of daily inflows into newly launched spot ETFs that continues to attract retail attention. Despite ongoing volatility and community debates over its long-term utility versus market speculation, holders remain focused on the potential impact of global regulatory milestones and increased banking partnerships on future liquidity.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is currently trending due to intensifying speculation surrounding its proprietary III-V-on-silicon photonics technology, which investors view as a critical, scalable solution for the power-efficiency bottlenecks in AI data centers. The community is actively discussing the stock's potential for high-volume commercial adoption, citing recent patent filings, government contracts, and the strategic addition of veteran industry leadership as key indicators that the company is transitioning from R&D to market-ready commercialization.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is seeing intense trading activity as market participants clash over conflicting narratives surrounding Middle East geopolitical disruptions and U.S. natural gas fundamentals. Community members are actively debating whether the ongoing supply-chain volatility in the Strait of Hormuz will trigger a sustained price breakout or if high storage levels and shoulder-season demand will ultimately lead to another technical collapse.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Orforglipron showed greater reductions in A1C blood sugar levels and body weight compared with the oral semaglutide.</li><li>Lilly has filed the drug for approval in more than 40 countries and plans to submit it in the U.S. later this year.</li><li>Eli Lilly is poised to lead the fast-growing GLP-1 market, JPMorgan Chase analyst Chris Schott reportedly said on Wednesday.</li></ul>Eli Lilly and Company (LLY) announced on Thursday that its experimental diabetes pill, Orforglipron, outperformed oral semaglutide in a large Phase 3 study, delivering stronger reductions in blood sugar and greater weight loss over 52 weeks.&nbsp;The 52-week ACHIEVE-3 trial enrolled 1,698 adults with type 2 diabetes and included four treatment groups - Orforglipron at 12 mg and 36 mg doses, and oral semaglutide at 7 mg and 14 mg doses.&nbsp;<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> were up 0.3% in pre-market trading.<h2 class="st-heading-2">Greater Reductions In A1C Blood Sugar Levels And Body Weight</h2>According to Lilly, Orforglipron showed greater reductions in A1C blood sugar levels and body weight compared with the oral semaglutide. The company said that the results were published in The Lancet. This study comes as the oral GLP-1 race intensifies across the sector.Orforglipron delivered meaningful improvements in several key heart health measures, including cholesterol levels, blood pressure, and triglycerides. Its safety profile in the ACHIEVE-3 study was consistent with that observed in earlier trials.The most common side effects for both orforglipron and oral semaglutide were nausea, diarrhea, vomiting, indigestion, and reduced appetite. However, discontinuation rates due to side effects were slightly higher with orforglipron compared to oral semaglutide.Lilly has filed the drug for approval in more than 40 countries and plans to submit it in the U.S. later this year.“The results of ACHIEVE-3 highlight the potential advantages of Orforglipron over oral semaglutide for type 2 diabetes: greater A1C reduction, more weight loss, and the ability to take it without food or water timing restrictions — that’s a combination that could matter significantly to people managing their disease day in and day out,” said Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health.<h2 class="st-heading-2">Lilly To Lead GLP-1 Market, JPMorgan Says</h2>Eli Lilly is poised to lead the fast-growing GLP-1 market, JPMorgan Chase analyst Chris Schott reportedly said. According to a CNBC article on Wednesday, Schott said Lilly’s “best-in-class” position and its direct-to-consumer platform, LillyDirect, could help it beat expectations as demand for weight-loss drugs rises.Schott estimates that by 2030, about 8 million patients could pay cash for GLP-1 treatments, benefiting Lilly. He also sees further upside when Lilly launches its oral drug. When Medicare begins covering GLP-1s in April, Schott believes Lilly will gain the most, with 4.5 million Medicare patients projected to use the drugs by 2030.Retail sentiment on Stocktwits remained ‘neutral’ over the past 24 hours.Year-to-date, the stock has fallen around 5%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/array-arry-stock-crashes-pre-market-200-dma-q4-results/cZTGfpIRIbu">ARRY Stock Cracks 26%, On Track To Hit 200-DMA For First Time In 3 Months – Retail Says Valuation Is ‘Cheap’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial

Investors are closely watching the oral GLP-1 race as competition intensifies across the sector.

Eli Lilly’s Oral GLP-1 Pill Showed Stronger A1C Drop, Weight Loss Than Oral Semaglutide 

Equity

<ul class="summary-bullets"><li>Vivtex will license select drug-delivery technologies to Novo Nordisk and could receive up to $2.1 billion.</li><li>The partnership looks to enable biologic drugs, which are typically given by injection due to poor absorption, to be delivered orally.</li><li>This partnership comes a day after Novo announced plans to cut U.S. prices for Ozempic and Wegovy by up to 50% from 2027.</li></ul>Novo Nordisk (NVO) announced on Wednesday that it has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes, and related conditions.Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk and could receive up to $2.1 billion in upfront payments, research funding, milestones, and tiered royalties on future sales.“Partnering with Novo Nordisk allows us to apply our platform across important metabolic disease areas, with the goal of enabling oral therapies that would otherwise require injection,” said Thomas von Erlach, CEO and co-founder of Vivtex.<a href="https://stocktwits.com/symbol/NVO">NVO shares</a> were down 1.8% at the time of writing.<h2 class="st-heading-2">Focus On Oral Delivery</h2>The partnership combines Novo’s expertise in peptide and protein therapies with Vivtex’s gastrointestinal screening tools, drug-delivery technologies, and AI-based platform aimed at improving drug absorption.The collaboration aims to enable biologic drugs, which are typically given by injection due to poor absorption, to be delivered orally. Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of any resulting products, it said.Oral obesity pills are seen as a key focus area in the obesity market, eliminating the need for injections and giving patients greater flexibility.This comes a day after Novo Nordisk <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-cut-ozempic-wegovy-prices-by-50/cZRvxJeR4C2">announced</a> plans to cut U.S. prices for Ozempic and Wegovy by up to 50% starting in 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes.One user sees the stock as a “short-term buy” option.<stembedurl>https://stocktwits.com/buddyopalosam/message/645859049</stembedurl>Another user said the stock was ‘undervalued.’<stembedurl>https://stocktwits.com/Matt_Y_/message/645842315</stembedurl>Year-to-date, the stock is down around 27%.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes

Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.

<ul class="summary-bullets"><li>The Danish pharmaceutical giant is expanding operations at its Athlone site.</li><li>CEO Mike Doustdar did not disclose how much the company plans to spend.</li><li>&nbsp;Doustdar said more than 240,000 people in the U.S. have already begun taking Wegovy in the form of pills.</li></ul>Novo Nordisk (NVO) is reportedly planning to ramp up its manufacturing footprint in Ireland as it prepares to increase production of its blockbuster Wegovy weight-loss pill for patients outside the U.S.&nbsp;According to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-02-12/novo-set-to-make-wegovy-pill-in-ireland-for-markets-outside-us?srnd=homepage-americas">report</a>, Novo’s CEO, Mike Doustdar, said the company will expand its facility in Ireland’s midlands region to support international demand for the oral version of Wegovy.Doustdar did not disclose how much the company plans to spend but emphasized that the expansion signals confidence in the product’s global prospects. The Danish pharmaceutical giant is expanding operations at its site in Athlone, a move that underscores its renewed push in the highly competitive obesity drug market.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk stock</a> inched 0.6% higher in Thursday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory while message volume shifted to ‘normal’ from ‘high’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Strong Early Demand</h2>The report cited that Wegovy’s pill form debuted in early January and quickly gained traction. Doustdar said more than 240,000 people in the U.S. have already begun taking the medication, calling it one of the most successful rollouts in the industry.Novo manufactures the U.S. supply domestically, while the Irish site will focus on serving markets beyond the U.S. On Wednesday, Doustdar said the company is planning to offer Wegovy injectables in vial form, similar to what competitor Eli Lilly and Company (LLY) has done.The latest push in Ireland comes as Novo works to regain momentum in the weight-management segment it once led. The company had previously warned about several challenges in 2026, including intense competition, lower selling prices, and the loss of patent protection for the main ingredient in its drugs, Wegovy and Ozempic, in some countries outside the U.S.NVO stock has declined by over 40% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-stock-rises-premarket-ahead-of-q4-earnings-r2-suv-reveal-nears-benchmark-sees-upside/cZRThmWR4AC">Rivian Stock Rises Premarket Ahead Of Q4 Earnings As R2 SUV Reveal Nears — Benchmark Sees Over 20% Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Novo Nordisk logo is seen with tablets, capsules, and syringes in this photo illustration in Brussels, Belgium, on August 9, 2025. 

Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report 

According to a Bloomberg report, Novo’s CEO, Mike Doustdar, said the company will expand its facility in Ireland’s midlands region to support international demand for the oral version of Wegovy.

<ul class="summary-bullets"><li>GDNF outperformed semaglutide, the active ingredient in Wegovy and Ozempic, across several key measures, Hoth said.</li><li>The 12-week study showed that female mice on a high-fat diet experienced a 10% to 15% reduction in weight gain with GDNF, whereas semaglutide showed no meaningful effect.</li><li>The company said GDNF reduced liver weight by 20% to 30% and prevented fat buildup, highlighting its potential to address fatty liver disease.</li></ul>Hoth Therapeutics (HOTH), on Tuesday, announced preclinical results from a Veterans Administration-backed study evaluating glial cell-derived neurotrophic factor (GDNF) as a potential treatment for obesity and metabolic-associated steatotic liver disease (MASLD).The company stated that in a head-to-head comparison, GDNF outperformed semaglutide, the active ingredient in weight-loss drugs such as Wegovy and Ozempic, across several key measures, including weight control, glucose tolerance, liver weight reduction, and adipose tissue control.<a href="https://stocktwits.com/symbol/HOTH">HOTH shares</a> were up over 5% in pre-market trading but reversed gains after the opening bell, trading 6% lower.<h2 class="st-heading-2">What Did The 12-Week Study Show?</h2>During the 12-week study, female mice on a high-fat diet experienced a 10% to 15% reduction in weight gain with GDNF, eventually entering a stabilization phase, whereas semaglutide showed no meaningful effect. Researchers noted that higher doses or longer durations could amplify GDNF’s effects.GDNF also normalized fasting glucose levels and improved responses to glucose challenges. Additionally, the therapy reduced liver weight by 20% to 30% and prevented fat buildup, highlighting its potential to address fatty liver disease, a common issue with obesity.“These results are a monumental step forward for Hoth and the fight against obesity. GDNF not only matched but exceeded semaglutide in critical areas, opening doors to a new era of safer, more effective therapies,” said Robb Knie, CEO of Hoth Therapeutics.<h2 class="st-heading-2">What’s Next?</h2>Hoth plans additional studies on liver pathology, lipid content, and gene and protein expression to better understand GDNF’s mechanism, with clinical trials targeted for 2027.Weight-loss drugs have become a central focus for the pharmaceutical industry, driving revenue growth for leaders like Eli Lilly and Novo Nordisk as other companies race to enter the booming market.The segment has been under regulatory spotlight in the aftermath of Hims &amp; Hers launching a compounded version of Wegovy last week, which the company has since withdrawn following legal notices from NOVO and the U.S. Food and Drug Administration.&nbsp;&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment turned ‘bullish’ from ‘neutral’ a day earlier, accompanied by ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/HOTH_jpg_40deb046fb.webp" alt="HOTH.jpg">One user called for patience amid the intraday decline.<stembedurl>https://stocktwits.com/Tom678/message/644546402</stembedurl>HOTH shares are down around 21% so far this year.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/why-did-azi-stock-reverse-gains-in-premarket/cZbUIHFR4Yy">AZI Stock Reverses Early Gains To Slump 30% In Pre-Market – What Happened?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

06 February 2025, Baden-Württemberg, Rottweil: A candlestick chart is opened in a trading platform on a smartphone. Photo: Silas Stein/dpa

Hoth Therapeutics' GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial

The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.

<ul class="summary-bullets"><li>Hims &amp; Hers said the compounded copy uses the same active ingredient as Wegovy but features a different formulation and delivery system.</li><li>The compounded pill will start at the introductory pricing for the first month for qualifying new customers under a five-month plan.</li><li>The pill is engineered to preserve the active ingredient during digestion and improve absorption.</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) rose 10% on Thursday after the company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.Hims &amp; Hers said the compounded copy uses the same active ingredient as Wegovy but features a different formulation and delivery system from the FDA-approved oral semaglutide. Novo Nordisk originally introduced Wegovy as a once-weekly injection and expanded the franchise earlier this year with the launch of an oral pill version.<h2 class="st-heading-2">$100 Cheaper Than Novo’s Wegovy</h2>Hims &amp; Hers said treatment plans using the compounded pill will start at an introductory $49 for the first month for qualifying new customers under a five-month plan. The remaining months are priced at $99 per month, payable in advance.According to Novo Nordisk’s website, Wegovy pills are priced at $149 per month for a 1.5 mg dose.Hims &amp; Hers stated that its compounded pill is engineered to preserve the active ingredient during digestion and improve absorption, offering an alternative for patients who want to avoid injections.Meanwhile, NVO shares fell nearly 6%.<h2 class="st-heading-2">Novo’s Pricing Challenges</h2>Earlier this week, Novo said it expects adjusted sales for full year 2026 to drop between 5% and 13%, with operating profit potentially falling by 13% due to pricing pressure, intensifying competition, and upcoming patent expiries for key ingredients in Wegovy and Ozempic in select markets outside the U.S.“Our 2026 guidance reflects a year of unprecedented pricing pressure,” CEO Mike Doustdar said in a call with journalists on Wednesday. Doustdar added that Novo would have to accept short-term pain to lift volumes, arguing that lowering prices would pay off in the long-run.The pill variant has already seen significant traction since its launch in January.“I can tell you, as of this week, we have over 170,000 people that are on the Wegovy pill, and most of that is self-pay,” Doustdar said in a call with analysts.Eli Lilly (LLY), the maker of weight-loss drugs Mounjaro and Zepbound, saw its shares fall 6.5%.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/HIMS">HIMS</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while chatter was ‘extremely high’ on the platform.One user saw the new launch as a “trend changing event.”<stembedurl>https://stocktwits.com/Dr_Stoxx/message/644091407</stembedurl>Another bullish user highlighted HIM’s latest developments.<stembedurl>https://stocktwits.com/tothebulltothewall/message/644092695</stembedurl>Year-to-date, the stock has declined around 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-b-stock-is-falling-despite-q4-beat/cZbZB3uR4VV">Barrick’s Q4 Earnings Beat Expectations – So, What Is Dragging The Stock Down In Premarket Today?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling?

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.

HIMS Stock Rises On Low-Cost Wegovy Alternative, Raising New Pricing Questions For Novo And Lilly

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.



Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook

Novo Nordisk slides 15% on a cautious 2026 sales outlook, but buybacks, leadership moves and Wegovy expansion put its ETFs in focus.

<ul class="summary-bullets"><li>In an interview with CNBC on Wednesday, CEO Doustdar said people should expect the company’s share price to go down before it goes back up.</li><li>NVO shares fell 4.5% in pre-market trading on Wednesday, extending Tuesday’s losses after the drugmaker issued a weak outlook for fiscal 2026.</li><li>Novo attributed the outlook to pricing pressure, and rising competition.</li></ul>Novo Nordisk (NVO) expects the U.S. Food and Drug Administration to decide on a higher-dose version of its Wegovy weight-loss drug in the first quarter of fiscal 2026.“Novo Nordisk submitted the high-dose semaglutide 7.2mg to the FDA in November. It’s under the CNPV pilot program, and we anticipate a decision during the first quarter of 2026,” Novo’s CEO Mike Doustdar said in a call with analysts on Wednesday.Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the Commissioner’s National Priority Voucher expedited program, a review decision is usually expected within one to two months after the filing is accepted.<a href="https://stocktwits.com/symbol/NVO">NVO shares</a> were down 4.5% in pre-market trading on Wednesday.<h2 class="st-heading-2">Weak 2026 Outlook Weighs On Shares&nbsp;</h2>The stock extended Tuesday’s losses of over 14% after the drugmaker issued a soft outlook for fiscal 2026, warning that sales and profit growth could decline amid mounting industry pressures. The company expects adjusted sales to fall between 5% and 13%, and operating profit could decline by up to 13%.Novo attributed the outlook to pricing pressure, rising competition, and upcoming patent expiries for the active ingredients in blockbuster drugs Wegovy and Ozempic in certain markets outside the U.S.In an interview with CNBC on Wednesday, Doustdar said people should expect the company’s share price to go down “before it comes back up.”The cautious forecast follows a disappointing 2025 performance. Novo reported net sales of DKK 309.06 billion ($48.9 billion), up 6% year over year but well below analyst estimates of DKK 346.97 billion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday decline, retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/NVO_jpg_0be70277b2.webp" alt="NVO.jpg" width="931" height="105"><figcaption>NVO's Sentiment Meter and Message Volumes at Premarket on Feb. 4, 2026 | Source: Stocktwits</figcaption></figure>One user said that the bearish guidance was a “self-inflicted wound.”<stembedurl>https://stocktwits.com/DJEuphoria/message/643918854</stembedurl>However, another user highlighted Novo’s strong grip in the diabetes and obesity markets.<stembedurl>https://stocktwits.com/Valconomics/message/643892305</stembedurl>NVO shares have plummeted around 40% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-lly-stock-jumps-fy26-guidance-zepbound-mounjaro/cZbSCjgR4Zl">LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance

Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is accepted.

Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre- Market On Weak Guidance

<ul class="summary-bullets"><li>Eli Lilly issued a revenue guidance between $80 billion and $83 billion for fiscal 2026</li><li>For the full year 2025, Eli Lilly’s revenue grew 45% to $65.18 billion.</li><li>CFO Lucas Montarce said the company expects to launch the multidose Zepbound within the next 30 days, according to a Bloomberg report.</li></ul>Shares of Eli Lilly (LLY) jumped 8% in pre-market trading on Wednesday, after the company reported better-than-expected fourth-quarter results and issued a revenue guidance between $80 billion and $83 billion for fiscal 2026, significantly above fiscal 2025 revenue.<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> were up 9.2% after the opening bell.Fourth-quarter revenue surged 43% to $19.3 billion, driven by volume growth from Mounjaro and Zepbound – signalling sustained momentum in its obesity and diabetes portfolio. Analysts had expected a revenue of $17.86 billion, according to Fiscal.ai data. Meanwhile, Q4 earnings increased by 51% to $7.39 per share on a reported basis, compared to Street estimates of $7.22 per share.For the full year, Eli Lilly’s revenue grew 45% to $65.18 billion. LLY expects earnings of $33.50 to $35 per share for full-year 2026.<h2 class="st-heading-2">Mounjaro And Zepbound Drive Revenue Growth</h2>Global revenue for Mounjaro surged 110% to $7.4 billion in Q4 2025, with U.S. sales rising 57% to $4.1 billion on strong demand despite lower realized prices. International revenue jumped to $3.3 billion from $899 million a year earlier, driven mainly by volume growth.U.S. Zepbound revenue climbed 122% to $4.2 billion, fueled by higher demand but partially offset by pricing pressure. Meanwhile, revenue from Verzenio, Eli Lilly’s drug to treat metastatic breast cancer, edged up 3% to $1.6 billion.<h2 class="st-heading-2">Eli Lilly’s Product Pipeline</h2>After the FDA authorized Lilly to market Zepbound in a multidose device last month, CFO Lucas Montarce said the company expects to launch the multidose pen within the next 30 days, according to a report by Bloomberg on Wednesday.In an interview with CNBC last month, CEO Dave Ricks said the upcoming Medicare coverage for obesity drugs could significantly boost the launch of its experimental weight-loss pill, Orforglipron. Ricks added that the company expects Medicare coverage to begin immediately after the drug’s launch.<h2 class="st-heading-2">LLY Pulls Ahead As NOVO Faces Headwinds</h2>Eli Lilly’s optimistic outlook stands in stark contrast to Novo Nordisk (NVO), which expects adjusted sales to decline between 5% and 13% and operating profit to drop by up to 13%. The company cited pricing pressure, intensifying competition, and upcoming patent expiries for the key ingredients in Wegovy and Ozempic in select markets outside the U.S.“This is just more evidence they are dominating the category,” Mizuho’s Jared Holz told Bloomberg of Eli Lilly’s obesity market position. “Novo is playing from behind and everyone knows it.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/LLY_jpg_1dcca688cf.webp" alt="LLY.jpg" width="933" height="102"><figcaption>LLY's Sentiment Meter and Message Volumes on Feb. 4, 2026 | Source: Stocktwits</figcaption></figure>One user said that Lilly proved that with “a good product comes great demand.”<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/643931351</stembedurl>LLY shares have gained around 25% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-fda-higher-dose-wegovy-nvo-stock-outlook/cZbjThlR4ZM">Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

LLY Stock Surges On Q4  Beat – Obesity, Diabetes Drugs Drive Strong FY26 Outlook

LLY Stock - Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug

FDA approval of NVO's oral Wegovy could reshape obesity care and lift healthcare ETFs, offering investors diversified exposure to the GLP-1 boom.

6 Top-Performing ETF Areas of Last Week 

Cannabis, metals, space and health care led ETF gains last week. WEED, CNBS, SIL, UFO, GDXJ, PLTM and OZEM outperformed despite tech weakness.

OZEM
Roundhill GLP-1 & Weight Loss ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest OZEM News

OZEMRoundhill GLP-1 & Weight Loss ETF